Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0028754
Disease: Obesity
Obesity
0.070 Biomarker disease BEFREE Patients with obesity and type 2 diabetes showed increased hepatic ghrelin O-acyltransferase transcripts as well as an increased hepatic apoptosis, pyroptosis, and compromised autophagy. 30137403 2019
CUI: C0028754
Disease: Obesity
Obesity
0.070 AlteredExpression disease BEFREE Recent studies suggest that decreasing the circulating octanoylated ghrelin level through the inhibition of GOAT activity, or simply by modulating the availability of its C8:0 substrate, might constitute a therapeutic strategy against obesity. 30103923 2018
CUI: C0028754
Disease: Obesity
Obesity
0.070 Biomarker disease BEFREE In addition, GOAT KO mice fed a medium-chain triglyceride (MCT) + high-sucrose diet showed a marked resistance to obesity and reduced feed efficiency. 28652538 2017
CUI: C0028754
Disease: Obesity
Obesity
0.070 Biomarker disease BEFREE Overall, inhibition of GOAT is a novel strategy for treatment of obesity and related metabolic disorders. 26732975 2016
CUI: C0028754
Disease: Obesity
Obesity
0.070 Biomarker disease BEFREE However, when fed on high-fat, high-sucrose diet, GOAT KO mice showed significantly reduced food intake and marked resistance to obesity, leading to amelioration of glucose metabolism. 26645250 2016
CUI: C0028754
Disease: Obesity
Obesity
0.070 AlteredExpression disease BEFREE Jejunum samples from humans with obesity showed a higher expression of GOAT (mRNA and protein), TPH1, and SERT mRNA compared with the nonobese humans (all P < 0.05). 26381270 2015
CUI: C0028754
Disease: Obesity
Obesity
0.070 Biomarker disease BEFREE GOAT may provide a critical molecular target in developing novel therapeutics for obesity and type 2 diabetes. 20038570 2009
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.040 Biomarker disease BEFREE Clinical Utility of Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Diagnostic Tool and Potential Therapeutic Target in Prostate Cancer. 31766715 2019
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.040 Biomarker disease BEFREE Clinical Utility of Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Diagnostic Tool and Potential Therapeutic Target in Prostate Cancer. 31766715 2019
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.040 AlteredExpression disease BEFREE Plasma ghrelin O-acyltransferase (GOAT) enzyme levels: A novel non-invasive diagnosis tool for patients with significant prostate cancer. 30256519 2018
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.040 AlteredExpression disease BEFREE Plasma ghrelin O-acyltransferase (GOAT) enzyme levels: A novel non-invasive diagnosis tool for patients with significant prostate cancer. 30256519 2018
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.040 Biomarker disease BEFREE In conclusion, plasmatic GOAT levels exhibit high specificity/sensitivity to predict PCa-presence compared with other PCa-biomarkers, especially in non-diabetic individuals, suggesting that GOAT holds potential as a novel non-invasive PCa-biomarker. 27693462 2016
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.040 Biomarker disease BEFREE In conclusion, plasmatic GOAT levels exhibit high specificity/sensitivity to predict PCa-presence compared with other PCa-biomarkers, especially in non-diabetic individuals, suggesting that GOAT holds potential as a novel non-invasive PCa-biomarker. 27693462 2016
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.040 AlteredExpression disease BEFREE We have demonstrated that GOAT mRNA and protein are expressed in the normal prostate and human prostate cancer tissue samples. 23879975 2013
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.040 AlteredExpression disease BEFREE We have demonstrated that GOAT mRNA and protein are expressed in the normal prostate and human prostate cancer tissue samples. 23879975 2013
Diabetes Mellitus, Non-Insulin-Dependent
0.030 AlteredExpression disease BEFREE Patients with obesity and type 2 diabetes showed increased hepatic ghrelin O-acyltransferase transcripts as well as an increased hepatic apoptosis, pyroptosis, and compromised autophagy. 30137403 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.030 AlteredExpression disease BEFREE Visceral adipose tissue from obese patients with type 2 diabetes showed higher levels of GOAT, increased adipocyte apoptosis and increased expression of the autophagy-related genes ATG5, BECN1 and ATG7. 22869322 2012
Diabetes Mellitus, Non-Insulin-Dependent
0.030 Biomarker disease BEFREE GOAT may provide a critical molecular target in developing novel therapeutics for obesity and type 2 diabetes. 20038570 2009
CUI: C0011847
Disease: Diabetes
Diabetes
0.020 AlteredExpression disease BEFREE Interestingly, GOAT levels in PCa-patients correlated with aggressiveness and metabolic conditions (i.e. diabetes). 27693462 2016
CUI: C0011847
Disease: Diabetes
Diabetes
0.020 Biomarker disease BEFREE Since the discovery that acylation of the serine-3 residue by ghrelin O-acyltransferase (GOAT) is essential for exerting its functions, GOAT has been regarded as an therapeutic target for attenuating appetite, and thus for the treatment of obesity and diabetes. 26645250 2016
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.020 Biomarker group BEFREE Since the discovery that acylation of the serine-3 residue by ghrelin O-acyltransferase (GOAT) is essential for exerting its functions, GOAT has been regarded as an therapeutic target for attenuating appetite, and thus for the treatment of obesity and diabetes. 26645250 2016
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.020 AlteredExpression group BEFREE Interestingly, GOAT levels in PCa-patients correlated with aggressiveness and metabolic conditions (i.e. diabetes). 27693462 2016
CUI: C0025517
Disease: Metabolic Diseases
Metabolic Diseases
0.020 Biomarker group BEFREE Overall, inhibition of GOAT is a novel strategy for treatment of obesity and related metabolic disorders. 26732975 2016
CUI: C0003125
Disease: Anorexia Nervosa
Anorexia Nervosa
0.020 GeneticVariation disease BEFREE Furthermore, a significant association of a GHSR gene variant with BN and that of a GOAT gene variant with AN have been found. 23601422 2013
CUI: C0003125
Disease: Anorexia Nervosa
Anorexia Nervosa
0.020 GeneticVariation disease BEFREE Based on our results we conclude that genetic variation in GOAT might be implicated in the etiology of AN. 21035823 2011